AKBA
Akebia TherNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$273.62M
P/E Ratio
—
EPS
$-0.08
Beta
0.35
52W High
$4.08
52W Low
$0.88
50-Day MA
$1.34
200-Day MA
$1.91
Dividend Yield
—
Profit Margin
-8.83%
Forward P/E
28.74
PEG Ratio
0.00
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $232.40M |
| Gross Profit (TTM) | $190.43M |
| EBITDA | $12.13M |
| Operating Margin | -2.76% |
| Return on Equity | -79.00% |
| Return on Assets | 2.02% |
| Revenue/Share (TTM) | $0.88 |
| Book Value | $0.10 |
| Price-to-Book | 10.00 |
| Price-to-Sales (TTM) | 1.18 |
| EV/Revenue | 0.697 |
| EV/EBITDA | 44.73 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -6.60% |
| Shares Outstanding | $268.26M |
| Float | $262.29M |
| % Insiders | 4.00% |
| % Institutions | 42.04% |
Historical Volatility
HV 10-Day
101.30%
HV 20-Day
110.98%
HV 30-Day
103.16%
HV 60-Day
81.45%
HV Rank
88.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($4.20 target)
1
Strong Buy4
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026